Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rapidscan Pharma Solutions (RPS) has received EU Commission marketing authorization for Rapiscan (regadenoson), a coronary vasodilator for use as a pharmacological stress agent in the diagnosis of coronary artery disease (CAD).
Subscribe to our email newsletter
Rapiscan is administered as a non-weight based bolus injection and is the first and only selective A2A adenosine receptor agonist to have a licence for use in this indication.
Rapiscan simulates the effects of exercise by temporarily increasing blood flow through the arteries of the heart, providing an option for such patients.
Rapiscan requires no dose adjustment for varying body weight and its bolus dosing method is rapid (taking just 10 seconds), cutting out the need for an infusion pump and its set-up.
Rapidscan Pharma Solutions founder, president and CEO Brent Blackburn said Rapiscan was designed to address the needs of patients and healthcare professionals who conduct MPI tests and its easier to use and better tolerated than the older agents.